Glofitamab

epkinly-approval-for-dlbcl-treatment

Jun 10, 2025

Abbvie-Genmab’s EPKINLY/TEPKINLY Performance in DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

top-10-oncology-drugs-launches-2023

Feb 24, 2023

Top 10 Expected Oncology Drug Launches in 2023

Pharma News and Updates for BMS, Mirati, Roche, Dermavant, Merck

May 31, 2022

Bristol-Myers Squibb’s Opdivo Approval; Mirati’s KRAS-inhibitor Adagrasib; J&J and Legend Biotech’s CAR-T Carvykti Approval; Roche’s Glofitamab; Arena Pharma’s Etrasimod Phase 3 Trials; FDA Approves Dermavant’s Vtama; FDA Approves Novartis’ Cell Therapy; NICE Approves Merck’s Keytruda

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper